Department of General Surgery, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Department of General Surgery, "Dr. Ion Cantacuzino" Clinical Hospital, Bucharest, Romania.
In Vivo. 2021 Jul-Aug;35(4):2495-2501. doi: 10.21873/invivo.12530.
BACKGROUND/AIM: Currently, the impact of diabetes mellitus (DM) on rectal cancer patients is complex and just partly elucidated. The purpose of this study was to investigate the impact of diabetes mellitus on rectal cancer patients focusing on tumor differentiation grade, neoadjuvant chemoradiotherapy (NACRT) response, disease-free (DFS) and overall (OS) survival.
Our study's population consisted of a group of 53 patients diagnosed with locally advanced rectal cancer, who underwent NACRT, followed by radical oncological surgery. This patient population was further divided into two groups according to diabetes presence.
Downstaging rates, local control, DFS, and OS were lower in the DM subgroup compared to the non-DM locally advanced rectal cancer patients.
The presence of DM at the time of diagnosis of locally advanced rectal cancer patients may be a negative predictive factor for response to neoadjuvant therapy, distant metastases, and local recurrences rates.
背景/目的：目前，糖尿病（DM）对直肠癌患者的影响较为复杂，部分原因尚未阐明。本研究旨在探讨糖尿病对直肠癌患者的影响，重点关注肿瘤分化程度、新辅助放化疗（NACRT）反应、无病生存（DFS）和总生存（OS）。
我们的研究人群由一组 53 名诊断为局部晚期直肠癌的患者组成，这些患者接受了 NACRT，随后进行了根治性肿瘤手术。根据是否存在糖尿病，将这组患者进一步分为两组。
DM 亚组的降期率、局部控制率、DFS 和 OS 均低于非 DM 局部晚期直肠癌患者。
在诊断局部晚期直肠癌患者时存在 DM 可能是对新辅助治疗、远处转移和局部复发率反应的负面预测因素。
